Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment

HOUSTON, June 2, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that recruiting has begun and the first patient has been enrolled in the Emory University Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children. The study is being conducted at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta.

The release as fetched from its publisher. moleculin.com ↗